<DOC>
	<DOCNO>NCT01056575</DOCNO>
	<brief_summary>This open label , sequential study midazolam ( dose 5 mg orally ) follow midazolam ( 5 mg orally ) give dose OC000459 100 mg twice daily 6.5 day . Twenty subject include ensure least 16 subject analysable PK data . PK sample midazolam 4-hydroxymidazolam plasma concentration continue include 24 hour dose midazolam occasion .</brief_summary>
	<brief_title>Study Evaluate Potential Interaction Between OC000459 CYP 450 3A4</brief_title>
	<detailed_description />
	<mesh_term>Indoleacetic Acids</mesh_term>
	<criteria>Judged good health screening ( blood test , physical examination , medical history ) Evidence clinically significant underlying medical condition opinion Investigator would represent risk study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>